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Prions containing misfolded prion protein (PrPSc) can be formed
with cofactor molecules using the technique of serial protein
misfolding cyclic amplification. However, it remains unknown
whether cofactors materially participate in maintaining prion
conformation and infectious properties. Here we show that with-
drawal of cofactor molecules during serial propagation of purified
recombinant prions caused adaptation of PrPSc structure accompa-
nied by a reduction in specific infectivity of >105-fold, to undetect-
able levels, despite the ability of adapted “protein-only” PrPSc
molecules to self-propagate in vitro. We also report that changing
only the cofactor component of a minimal reaction substrate mix-
ture during serial propagation induced major changes in the strain
properties of an infectious recombinant prion. Moreover, propa-
gation with only one functional cofactor (phosphatidylethanol-
amine) induced the conversion of three distinct strains into
a single strain with unique infectious properties and PrPSc struc-
ture. Taken together, these results indicate that cofactor molecules
can regulate the defining features of mammalian prions: PrPSc
conformation, infectivity, and strain properties. These findings
suggest that cofactor molecules likely are integral components
of infectious prions.
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Transmissible spongiform encephalopathies such as Creutz-feldt–Jakob disease, bovine spongiform encephalopathy,
chronic wasting disease, and scrapie are caused by uncon-
ventional infectious agents termed “prions” that lack infor-
mational nucleic acids (1). The most fundamental event in the
formation of infectious prions is the conformational change of
a host-encoded glycoprotein termed “PrPC” into a misfolded
conformer termed “PrPSc” (2, 3); purified PrPSc molecules can
induce the conversion of additional PrPC molecules into the
PrPSc conformer in a self-propagating manner (4, 5).
Much effort has been made to determine the chemical nature
of infectious mammalian prions. According to the “protein-only”
hypothesis, infectious prions potentially are composed solely of
PrPSc (6–9). However, several groups have shown that relatively
low levels of specific infectivity using only pure PrP molecules as
a substrate (10–12). In contrast, chemical reactions containing
purified PrP molecules plus nucleic acid and lipid molecules
spontaneously generate and propagate PrPSc molecules associ-
ated with moderate levels of specific infectivity (5). Additional
evidence that cellular factors other than PrP influence the effi-
ciency of prion propagation is provided by studies showing that
various clonal lines of cultured neuroblastoma cells have differ-
ent levels of susceptibility to prion infection (13, 14). It is un-
known currently whether cofactor molecules are simply catalysts
for prion formation or whether they also play an essential role
maintaining a specific infectious conformation of PrPSc. Studies
with purified prions containing a photolabile oligonucleotide
cofactor showed that polyanionic cofactors are not required to
maintain infectivity (15), but the prions used in those studies
contained copurified lipids, whose role in maintaining infectivity
remains unknown.
Interestingly, prions can exist as different “strains” charac-
terized by distinctive clinical and neuropathological features that
are recapitulated faithfully upon serial passage within the same
animal species (16, 17). Recent studies suggest that individual
strains of mammalian prions may be composed of a mixture of
PrPSc conformers and that the relative distribution of those
conformers may be subject to selective pressure during the
process of strain adaptation, e. g., by transmission between dif-
ferent animal species (18) or passage in cloned cell lines (19).
However, the molecular mechanism by which a variety of PrPSc
conformers can be produced and selected during the process of
strain adaptation has not yet been elucidated. One possible
mechanism is that each PrPSc conformer might require a unique
set of cofactors to propagate efficiently, and the distribution of
these putative cofactor molecules may vary in different animal
species and cell types. Consistent with this concept, recon-
stitution studies have revealed the existence of multiple classes of
cofactors for prion propagation in vitro (20).
We recently identified the endogenous activity responsible for
facilitating mouse prion propagation in vitro (20) as phosphati-
dylethanolamine (PE) (21). PE robustly facilitates the formation
of infectious recombinant mouse prions as a solitary cofactor
without RNA, providing a unique tool to test whether cofactor
molecules can regulate PrPSc conformation, prion strain proper-
ties, and infectivity in a minimal in vitro prion propagation system.
Results
Withdrawal of Cofactor During Serial Propagation Produces an
Adapted Self-Propagating “Protein-only” PrPSc Conformer. We seri-
ally propagated a previously described recombinant prion strain
(22) (termed the “OSU strain”) for more than 30 rounds in
seeded serial protein misfolding cyclic amplification (sPMCA)
reactions using a substrate mixture containing pure α-helical
recombinant prion protein (recPrP) molecules and a purified
cofactor preparation containing a mixture of mouse brain
phospholipids, of which the only active component is PE. Under
these conditions, the propagation of an ∼18-kDa PrPSc con-
former (which we term “OSU cofactor PrPSc”) is maintained
indefinitely (Fig. 1A, first blot). To test whether cofactor mole-
cules are required to maintain a self-propagating PrPSc confor-
mation, we used OSU cofactor PrPSc molecules to seed sPMCA
reactions with recPrP as the sole substrate (i.e., without the co-
factor preparation). These experiments produced two different
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sets of outcomes. In ∼40% of these experiments, PrPSc propa-
gation could not be sustained following cofactor withdrawal (Fig.
1A, second blot), but in ∼60% of the experiments we un-
expectedly observed step-wise adaptation of the ∼18-kDa OSU
cofactor PrPSc seed into a self-propagating ∼16-kDa protease-
resistant recPrPSc band (which we term “OSU protein-only
PrPSc”) (Fig. 1A, third and fourth blots). The resistance of the
OSU protein-only PrPSc conformer to digestion with a 25:1 mass
ratio of proteinase K to recPrP, as well as its formation in the
absence of 0.1% SDS, distinguishes it from a previously reported
recPrP sPMCA product (23). Once formed, the OSU protein-
only PrPSc conformer could be propagated indefinitely in
sPMCA reactions (Fig. 1B) in the same manner as the cofactor
PrPSc conformer. Interestingly, the OSU protein-only PrPSc
conformer did not trigger formation of ∼18-kDa recPrPSc when
either the purified cofactor preparation or synthetic PE was re-
stored to the substrate mixture (Fig. S1), indicating that the
switch from the cofactor PrPSc conformation to the protein-only
PrPSc conformation is unidirectional.
Cofactor PrPSc and Protein-only PrPSc Molecules Have Similar Ultra-
structural Features. To compare the ultrastructural characteristics
of the OSU cofactor PrPSc conformer with those of the OSU
protein-only PrPSc conformer, we performed atomic force mi-
croscopy on both types of PrPSc molecules. This comparison
revealed that the two conformers generally displayed similar
ultrastructural features (the predominant species observed in both
samples being an ∼2-nm sphere), although the distribution of
heights differed slightly between the two samples (Fig. S2A and B).
Rings ∼100 nm in diameter also were seen in ∼1% of the scanned
fields in the sample containing protein-only PrPSc molecules (Fig.
S2A, Right). Interestingly, these recPrPSc spheres and rings are
reminiscent of previously described “dots and rings” formed by
yeast prions (24, 25). No fibrils were observed in scans of either
OSU cofactor PrPSc or OSU protein-only PrPSc molecules.
Protein-only PrPSc Molecules Are Not Infectious in Vivo and Cannot
Trigger Native PrPSc Formation in Vitro.We next sought to compare
the infectivity of OSU cofactor PrPSc and OSU protein-only
PrPSc molecules. To do so rigorously, we generated a closely
matched set of internally controlled samples. Substrate mixtures
were prepared from two aliquots of a single stock solution of
recPrP in buffer. Then purified cofactor was added to one of the
aliquots to complete the cofactor PrPSc mixture, and an equal
volume of water was added to the other aliquot to make the
protein-only mixture. We then simultaneously propagated OSU
cofactor PrPSc and OSU protein-only PrPSc molecules in their
appropriate substrate mixtures using equidistant, concentric
locations of a single circular microplate horn. SDS/PAGE of the
final round products shows that similar quantities of PrPSc were
produced in all the processed samples (Fig. S3). Thus, the
availability of these well-matched and simultaneously processed
samples provided a unique opportunity to test in isolation the
role of cofactor molecules in maintaining prion infectivity.
We performed end-point titration bioassays of these simulta-
neously processed samples in wild-type C57BL mice. The results
of these assays indicate that recPrPSc molecules formed with
cofactor caused scrapie at dilutions from 10−1 to 10−5 (Table 1),
as confirmed by pathology (Fig. S4) and Western blot (Fig. S5).
Based on the end-point titration data and Western blot quanti-
tation of PrPSc in the inoculum, the specific infectivity of OSU
cofactor recPrPSc molecules is ∼2.2 × 106 LD50 units/μg PrP. In
contrast, OSU protein-only recPrPSc molecules derived from the
same original recPrPSc seed failed to cause scrapie in mice even
at the highest concentration tested (Table 1). The brains of age-
matched, asymptomatic animals inoculated with protein-only
recPrPSc molecules were histologically normal (Fig. S4) and
lacked PrPSc as judged by Western blot (Fig. S5).
To determine whether the >105-fold difference in specific
infectivity is caused by differences in the ability of the two PrPSc
conformers to trigger native PrPC conversion, we compared the
ability to these two conformers to seed sPMCA reactions using
crude brain homogenate as substrate. The results show that al-
though the OSU cofactor PrPSc molecules effectively seeded
PrPSc formation, the OSU protein-only PrPSc conformer failed to
trigger native prion formation in all three rounds of the sPMCA
assay (Fig. 2). Moreover, the inability of the OSU protein-only
conformer to trigger native PrPC conversion could not be over-
come by preliminary propagation for four rounds in a substrate
mixture containing PE before sPMCA with brain homogenate
(Fig. S6), confirming that the switch to the inactive conformation
is most likely irreversible and that phospholipid molecules do not
simply protect or enhance delivery of PrPSc. Collectively, the
results of the bioassay and sPMCA experiments show that con-
trolled removal of cofactor causes adaptation of self-propagating,
protease-resistant recPrPSc molecules into a conformation that is
unable to trigger native PrPSc formation in vivo or in vitro.
Cofactor Molecules Are Physically Associated with PrPSc Aggregates.
Because the foregoing results indicate that a cofactor prepara-
Table 1. Bioassay of in vitro-generated recombinant PrPSc
molecules in normal C57BL mice
Inoculum Dilution n/n0 IP (days)*
Cofactor PrPSc 10−1 7/7 356 ± 12
10−2 3/3 451 ± 16
10−3 4/4 481 ± 42
10−4 4/4 501 ± 28
10−5 1/3 539
10−6 0/4 >570
Protein only PrPSc Sample A 10−1 0/4 >570
10−2 0/4 >570
10−3 0/4 >570
10−4 0/4 >570
Protein only PrPSc Sample B 10−1 0/4 >570
10−2 0/4 >570
10−3 0/4 >570
10−4 0/4 >570
*Incubation period (IP) of scrapie sick animals, mean ± SE.
Fig. 1. Adaptation of autocatalytic PrPSc molecules. Western blots of recon-
stituted sPMCA reactions. −PK, samples not subjected to proteinase K di-
gestion; all other samples were proteolyzed. (A) All reactions initially were
seeded with OSU cofactor PrPSc molecules and subsequently were propa-
gated in substrate mixtures with or without cofactor, as indicated. (B) On-
going propagation of OSU protein-only PrPSc molecules in substrate mixture
lacking cofactor.
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tion containing PE is required to maintain PrPSc infectivity,
we sought to determine whether PE becomes physically in-
corporated into the recombinant prion aggregates as they are
formed. To study this question, we used the compound 1-oleoyl-
2-{12-[(7-nitro-2–1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-sn-
glycero-3-phosphoethanolamine [18:1–12:0 nitrobenzoxadiazole
(NBD):PE], in which a fluorescent NBD group is covalently at-
tached as a probe to the C2 fatty acid adduct of synthetic PE. We
performed seeded four-round sPMCA reactions with a substrate
mixture containing recPrP and NBD-PE to produce NBD-PE
PrPSc molecules (Fig. 3A). We then used a microscopic dual-
channel fluorescence assay to determine whether NBD-PE be-
came incorporated into complexes with recPrPSc during the
sPMCA reactions. The results of this assay show that the fluo-
rescent cofactor is present and colocalizes with PrPSc aggregates
detected by antibody staining (Fig. 3B), indicating that the
recombinant prions do contain PE in addition to PrPSc mole-
cules. Quantitation of total NBD fluorescence within the washed
recPrPSc pellet suggests a protein:lipid molar ratio of ∼1:4. It is
unlikely that the fluorescent lipid molecules are weakly bound to
the solvent-accessible surface of PrPSc aggregates because the
samples were washed extensively with detergent before analysis.
Cofactor-Induced Modulation of Strain-Dependent Neurotropism and
Prion Incubation Times. The observation that cofactor molecules
participate in maintaining the infectious conformation of PrPSc
raises the possibility that they also may play a role in encoding
strain properties. Castilla et al. (26) previously established that
several different murine prion strains maintain their specific
biochemical and infectious properties when serially propagated
in vitro using crude brain homogenate as a substrate. Therefore,
we decided to use our chemically defined in vitro prion propa-
gation system to test whether different prion strains are able to
maintain distinctive properties when only one active cofactor
(PE) is available to form new PrPSc molecules.
For these experiments, we used the original OSU isolate [which
was produced de novo in sPMCA reactions from recPrP, 1-pal-
mitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), and RNA
substrates (22)] as well as two easily distinguishable native mouse
prion strains (301C and Me7) to seed a uniform substrate mixture
containing recPrP and purified cofactor preparation. For each
strain, sPMCA produced self-propagating cofactor recPrPSc mol-
ecules with a protease-resistant core ∼18 kDa in size (Fig. S7A).
We inoculated wild-type C57BL mice with cofactor PrPSc
molecules produced by 18-round sPMCA propagation of each
strain along with the original seed material (input samples) for
each strain and negative control samples. Mock-propagated sam-
ples originally seeded with each strain and processed in parallel
with the experimental samples were noninfectious, confirming
that 18 rounds of sPMCA were sufficient to eliminate the orig-
inal infectious seeds by serial dilution (Table 2). In contrast,
cofactor PrPSc molecules derived from all three strains caused
scrapie in the inoculated animals. Interestingly, the incubation
periods for cofactor PrPSc molecules were at least twice as long
as the incubation periods caused by the input samples for all
three strains (Table 2).
The defining characteristic of mammalian prion strains is se-
lective neurotropism in infected hosts, and therefore we analyzed
the neuropathological profiles of mice inoculated with input and
cofactor PrPSc molecules by scoring brain regions for spongiform
change (vacuolation) and PrP deposition (immunohistochemis-
try). As expected, the three input strains could be distinguished
from each other easily by their vacuolation and PrP deposition
profiles (Fig. 4 A and E). However, the vacuolation and PrP
deposition profiles for all three cofactor PrPSc samples derived
from those strains were similar to each other (Fig. 4 B and F) and
were different from their parent strains (i.e., the three input
samples) (compare vacuolation profiles in Fig. 4 A and B and PrP
deposition profiles in Fig. 4 E and F).
At a microscopic level, the most dramatic examples of cofactor-
induced changes in neurotropism that we observed were in (i) the
degree of vacuolation caused by OSU input versus OSU cofactor
PrPSc molecules in the cerebral cortex and hypothalamus (Fig. S8)
and (ii) the patterns of PrP immunodeposition induced by 301C
input versus 301C cofactor PrPSc molecules in the cerebral cortex
(where 301C input causes deposition selectively in cortical layers
III–IV, as indicated by the arrowhead in Fig. S9).
It is important to note that both the OSU input and OSU
cofactor PrPSc samples were produced by propagation of the
original OSU seed (containing POPG and RNA) in sPMCA
reactions using recPrP substrate. The only experimental difference
between these two samples was a change in the cofactor compo-
nent from POPG/RNA to the purified phospholipid cofactor
preparation of the sPMCA substrate mixture. Therefore, in this
case, the dramatic differences in neurotropism between the OSU
input and OSU cofactor PrPSc samples (Fig. 4, red squares;
compare Fig. 4 A and B with F and E) can be attributed un-
ambiguously to the change in cofactor composition and not to
the use of recPrP substrate or to the sPMCA technique per se in
the experiment.
Because the only component of the purified cofactor prepa-
ration able to facilitate PrPSc propagation is PE, we hypothesized
that PE alone might be responsible for producing and main-
taining the characteristics of the cofactor PrPSc strain, which
differ markedly from those of each of the three input strains. To
test this hypothesis, we propagated all three sets of cofactor
PrPSc molecules into a substrate mixture containing only recPrP
and synthetic PE for 18 rounds, yielding a set of “PE PrPSc”
Fig. 2. Seeding of brain homogenate sPMCA reactions. Western blot of
three-round sPMCA reactions using normal mouse brain homogenate sub-
strate seeded with various samples as indicated. −PK, samples not subjected
to proteinase K digestion; all other samples were proteolyzed. Native PrPSc
was isolated as PrP27-30 molecules from the brains of Me7-infected mice
as previously described (35), and PrP amyloid was generated as previously
described (36).
Fig. 3. NBD-PE PrPSc colocalization assay. (A) Western blot of a four-round
sPMCA reaction using recPrP and NBD-PE as substrate. −PK, samples not
subjected to proteinase K digestion; all other samples were proteolyzed.
(B) Dual-channel fluorescence micrographs showing representative images
of the final product of the sPMCA reaction shown in A, after purification
with detergent washes as described in Experimental Procedures. PrPSc
aggregates immunostained with anti-PrP mAb D13 and Alexa Fluor 568-
labeled secondary antibody are shown in red (PrP), and colocalized NBD-PE
molecules are shown in green (NBD-PE).
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molecules also ∼18 kDa in size (Fig. S7B). When inoculated into
C57BL mice, all three sets of PE PrPSc molecules caused scrapie
with long incubation periods comparable to those induced by
cofactor PrPSc molecules (Table 2). Neuropathological studies
showed that all three sets of PE PrPSc inocula induced similar
patterns of vacuolation and PrP deposition in the brains of in-
oculated mice (Fig. 4 C and G). Moreover, these patterns were
similar to those induced by cofactor PrPSc molecules (compare
vacuolation profiles in Fig. 4 C and B and PrP deposition profiles
in Fig. 4 F and G).
Statistical analysis confirmed that vacuolation patterns of
the three cofactor PrPSc samples were significantly different
(Wilcoxon rank-sum test P < 0.05) from their corresponding
three input strains in 18 of 21 comparisons (seven brain regions
and three output inocula). Similarly, PrP immunodeposition of
OSU input- versus OSU cofactor PrPSc-inoculated animals
showed statistically significant differences in seven of eight brain
regions, Me7 input- versus Me7 cofactor PrPSc-inoculated ani-
mals showed statistically significant differences in two of eight
brain regions, and 301C input- versus 301C cofactor PrPSc-
inoculated animals showed statistically significant differences in
five of eight brain regions. Additional statistical analysis showed
no evidence to reject the hypothesis that the vacuolation and PrP
deposition profiles of the six output (cofactor and PE) strains
came from a single distribution. In contrast, when the analysis
was repeated after including the three input strains and six
output strains, the null hypothesis was rejected for six of the
eight brain regions (all P < 0.04).
Cofactor-Induced Modulation of Strain-Dependent PrPSc Confor-
mation. In some instances, differences in the conformation of
PrPSc molecules associated with different prion strains can be
detected by biochemical assays. We therefore compared bio-
chemical characteristics of PrPSc molecules in the brains of
infected mice by SDS/PAGE/Western blotting and urea de-
naturation assays. Western blotting showed that all three sets of
cofactor PrPSc inocula induced the formation of protease-
resistant PrPSc molecules with similar glycoform profiles (domi-
nated by diglycosylated PrPSc) and migration after enzymatic
deglycosylation (Fig. 5, lanes 1–3). Similarly, the protease-
resistant PrPSc molecules in the brains of animals infected with all
three sets of PE PrPSc inocula had glycoform profiles and migra-
tion patterns that were similar to those of PrPSc molecules in the
brains of animals infected with cofactor PrPSc inocula (Fig. 5,
compare lanes 7–9 with lanes 1–3). In contrast, protease-resistant
PrPSc molecules induced by input 301C prions were ∼2 kDa
smaller in size (Fig. 5, lane 4), and PrPSc molecules induced by
input OSU recombinant prions had a characteristic glycoform
profile in which diglycosylated PrPSc was the least abundant
species (Fig. 5, lane 6).
We used a urea denaturation assay to compare PrPSc stability
in the brains of mice infected with the various sets of inocula.
The results revealed significant differences in the conformational
stability of PrPSc molecules in the brains of animals inoculated
with the three input strains (Fig. 6A). PrPSc molecules induced
by the OSU input strain were the most resistant to urea de-
naturation [(Urea)1/2 = 3.8 M], whereas input Me7-induced
PrPSc molecules were the most susceptible to denaturation, with
[(Urea)1/2 = 2.0 M]. In contrast, the PrP
Sc molecules in the
brains of mice inoculated with the three sets of cofactor PrPSc
molecules (Fig. 6B) as well as the three sets of PE PrPSc inocula
(Fig. 6C) all displayed similar denaturation profiles [(Urea)1/2 =
1.5–2.2 M]. It is interesting that the relatively weak resistance to
denaturation exhibited by PrPSc molecules in cofactor PrPSc- and
PE PrPSc-inoculated mice was unexpected, given their long
scrapie incubation times (Table 2), because it had been suggested
previously that long incubation times in mice usually are corre-
lated with a high level of PrPSc conformational stability (27).
Strain Adaptation upon Serial Passage in Vivo. Finally, we in-
vestigated whether the unique strain properties of cofactor PrPSc
and PE PrPSc molecules would be maintained upon serial pas-
sage in mice. The results of these analyses showed that all six sets
of serially passaged prions (i.e., the brains of cofactor PrPSc- and
PE PrPSc-inoculated animals for all three strains) displayed in-
cubation times (Table 2), patterns of neurotropism (Fig. 4 D and
H), and PrPSc biochemical characteristics (Fig. 6 and Fig. S10)
that were similar to each other. These results confirm that all the
cofactor PrPSc and PE PrPSc prions had converged into a single
strain. The biochemical characteristics of the PrPSc molecules in
the brains of animals inoculated with each of the serially pas-
saged prions also were indistinguishable from those of the PrPSc
molecules in the brains of animals directly inoculated with cofactor
PrPSc and PE PrPSc prions (Fig. 6 and Fig. S10). However, the
Table 2. Bioassay of native and in vitro-generated recombinant PrPSc molecules in normal
C57BL mice
Seed (strain) Inoculum Dilution n/n0 IP (days)*
OSU Input recPrPSc 100 5/5 173 ± 1
OSU Cofactor recPrPSc 10−1 7/7 356 ± 12
OSU Synthetic PE recPrPSc 10−1 8/8 381 ± 11
OSU Serial Passage- Synthetic PE recPrPSc 1% wt/vol 8/8 175 ± 4
OSU Mock sPMCA control 10−1 0/4 >570
Me7 Input brain homogenate 10−1 7/7 158 ± 7
Me7 Cofactor recPrPSc 10−1 8/8 396 ± 20
Me7 Synthetic PE recPrPSc 10−1 6/6 417 ± 21
Me7 Serial Passage- Synthetic PE recPrPSc 1% wt/vol 8/8 166 ± 3
Me7 Mock sPMCA control 10−1 0/4 >510
301C Input brain homogenate 10−1 7/7 182 ± 4
301C Cofactor recPrPSc 10−1 8/8 401 ± 11
301C Synthetic PE recPrPSc 10−1 6/7 360 ± 9†
301C Serial Passage- Synthetic PE recPrPSc 1% wt/vol 8/8 173 ± 3
301C Mock sPMCA control 10−1 0/4 >510
None Cofactor mixture 10−1 0/4 >570
None Synthetic PE mixture 10−1 0/4 >570
*Incubation period (IP) of scrapie sick animals, mean ± SE.
†Ongoing experiment. n/n0 = number of animals diagnosed with prion disease/number of animals inoculated.
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Fig. 4. Regional neuropathology of infected mice. (A–D) Profiles of vacuolation scores of animals inoculated with samples containing (A) input prions, (B)
cofactor PrPSc molecules, (C) PE PrPSc prions, or (D) serial-passage PE PrPSc prions. (E–H) Profiles of PrP deposition scores of animals inoculated with samples
containing (E) input prions, (F) cofactor PrPSc molecules, (G) PE PrPSc prions, or (H) serial-passage PE PrPSc prions. Prion strains: OSU, red squares; Me7, blue
circles; 301C, green triangles. Brain regions: I–II, cerebral cortical layers 1 and 2; III–IV, cortical layers 3 and 4; V–VI, cortical layers 5 and 6; BS, brainstem; Cb,
cerebellum; CC, cerebral cortex (all layers); H, hippocampus; HT, hypothalamus; Mid, midbrain; T, thalamus. Mean values ± SEM are shown; n = 5.
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prion incubation times and patterns of neurotropism of the
second-passage prions differed from those of the cofactor PrPSc
and PE PrPSc prions (Table 2 and Fig. 4; compare vacuolation
profiles in Fig. 4 C and D and PrP deposition profiles in Fig. 4 G
and H), indicating that additional strain adaptation occurred
during in vivo propagation, presumably because of the availability
of additional cellular cofactors in the intact brain.
Discussion
In this paper we used a minimal in vitro prion propagation sys-
tem to study directly the effect of cofactor molecules on PrPSc
conformation, infectivity, and strain properties. Our results show
that withdrawal of cofactor during serial propagation of purified
recombinant prions caused adaptation of PrPSc conformation,
manifest as an ∼2-kDa difference in the size of the protease-
resistant core. Moreover, a direct comparison between samples
of cofactor-containing and protein-only PrPSc molecules (pro-
duced in parallel from the same seed and substrate mixture)
using an end-point titration bioassay revealed that phospholipid
molecules play a quantitatively large role in maintaining the in-
fectivity of in vitro-generated prions. In contrast, RNA molecules
are not required to maintain infectivity in the presence of cop-
urified lipids and therefore can be considered nonessential (15).
Our results may help explain why relatively modest levels of
infectivity are produced when purified recPrP (presumably con-
taining little or no bacterial lipid) has been used as a solitary
substrate to generate prions by a variety of protocols (10–12, 28).
Although we cannot rule out the possibility that a yet un-
identified protocol could produce highly infectious prions from
recPrP alone, the results of our internally controlled experiment
in which an alternative, noninfectious PrPSc conformation is
propagated after cofactor withdrawal suggest that this scenario is
not likely to occur and that the infectious conformation of PrPSc
is structurally dependent on physical interactions between PrP
and essential cofactor molecules.
We also found that cofactor molecules seem to exert an in-
fluence on prion strain properties in our minimal prion propa-
gation system. Most importantly, we found that the strain
properties of recombinant prions initially formed from recPrP
substrate by sPMCA with POPG and RNA molecules could be
altered during subsequent serial propagation by changing only
the cofactor component (from POPG/RNA to PE) to form
a unique output strain characterized by a long scrapie incubation
period and unique neuropathological and biochemical charac-
teristics. These results directly show that a change in cofactor,
rather than the absence of cellular processes, is sufficient to
cause a change in prion strain properties. Additional experi-
ments revealed that that two different native prion strains also
adapted into the same unique output strain when propagated
in vitro with PE as the only available cofactor. Given the clear
differences among three input prion strains, our results indicate
that a single cofactor can selectively pressure multiple prion
strains to converge into a single, phenotypically distinct strain.
Prior studies have shown that strain properties are not altered
either randomly or as a result of cross-contamination in seeded
sPMCA reactions (26, 29). These potential pitfalls also are very
unlikely to explain the results of our experiments because (i)
a completely unique strain was produced reproducibly in all six
independent samples containing PE; (ii) each sample was propa-
gated in its own sonicator horn; (iii) each sample was propagated
at a different time; (iv) the reaction tubes were sealed with Par-
afilm, a maneuver that eliminates cross-contamination during
sPMCA (30); and (v) the OSU input and OSU cofactor PrPSc
samples exhibit different strain characteristics, but both samples
are products of sPMCA reactions with recPrP substrate seeded
with OSU prions.
It is interesting to speculate that individual prion strains may
propagate most efficiently with their own unique set of endog-
enous cellular cofactors and that the levels of these particular
cofactors may vary among cell types and animal species. Various
types and combinations of cofactors easily could account for
the natural diversity of prion strains. This “cofactor selection”
hypothesis provides a potential molecular mechanism for the
generation of multiple PrPSc conformations (31) (potentially
because of the interaction of PrP with multiple potential cofac-
tors) that can adapt in response to selective pressure in cell
cultures (19) or cross-species transmission (18) as well as for the
phenomenon of strain-specific neurotropism (if strain-specific
cofactors are enriched selectively in different brain regions). This
hypothesis also is consistent with the generation of unique strain
phenotypes that have been reported when infectious prions are
produced in the absence of endogenous cofactors (11, 12, 28).
Cofactors capable of maintaining the properties of native murine
prion strains in vitro are present in crude brain homogenate,
because sPMCA in brain homogenate substrate has been shown
to preserve the strain-specific characteristics of 301C and other
murine prions (26, 29).
Taken together, our results show that cofactor molecules such
as PE modulate PrPSc structure in infectious prions, enabling the
formation of the infectious conformer and restricting strain
properties. These findings suggest that cofactor molecules are
likely integral and essential components of infectious prions. It
is possible that cofactor molecules also may play a critical role
in the pathogenesis of other neurodegenerative diseases in
which protein misfolding can spread through the brain, such as
Alzheimer’s disease, Parkinson disease, and amyotrophic lateral
sclerosis (32).
Experimental Procedures
Reagents. The Me7 (mouse adapted scrapie originally from sheep) and 301C
(mouse adapted bovine spongiform encephalopathy prions) prion strains
used in this study were kindly provided by Stanley Prusiner (University of
California, San Francisco) and Claudio Soto (University of Texas, Houston),
respectively. The recombinant strain designated “OSU” is the recPrPSc sample
originally produced de novo by F.W. as previously described (22) and sub-
sequently propagated with purified cofactor by N.R.D. The pET-22b(+) ex-
pression plasmid (catalog no. 69744), Overnight Express Autoinduction
System (catalog no. 71300–3), Bug Buster 10× plus Lyso catalog no. nase Kit
(catalog no. 71370), and Ni-NTA His-Bind Superflow Resin (catalog no. 70691)
were purchased from EMD Chemicals. Micrococcal (S7) nuclease (catalog no.
107921) was purchased from Roche. Thermolysin (catalog no. 88303) was
purchased from Sigma. Synthetic plasmalogen phosphatidylethanolamine (PE)
(catalog no. 852758P) was purchased from Avanti Polar Lipids.
Animal Care. Female C57BL mice were purchased from Charles River Labora-
tories (Wilmington, MA). Mice were housed in microisolation cages and han-
dled in strict accordance with good animal practice, as defined by the Guide
for theCare andUseof LaboratoryAnimals of theNational Institutes ofHealth.
Fig. 5. Glycoform distribution and electrophoretic mobility of PrPSc mole-
cules in the brains of infected mice. (Upper) Western blots of brain
homogenate samples prepared from animals inoculated with samples con-
taining input prions, cofactor PrPSc, and PE PrPSc molecules derived from
different prion strains, as indicated. All samples were subjected to limited
proteolysis. (Lower) Samples also were deglycosylated by treatment with
PNGase F, as indicated (+), before SDS/PAGE.
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TheDartmouthCollege InstitutionalAnimalCareandUseCommitteeapproved
the animal work (assurance number A3259-01). Inoculations were performed
under isoflurane anesthesia, and all efforts were made to minimize suffering.
Recombinant Mouse PrP Expression and Purification. Amplified DNA sequen-
ces coding for mouse PrP 23–231 were ligated into the pET-22b(+) expression
vector (EMD Chemicals), and sequences were verified. The expression vector
Fig. 6. Analysis of PrPSc conformational stability. Urea denaturation assay showing PrPSc levels in samples of brain homogenates prepared from animals
inoculated with samples derived from different prion strains. Inocula were (A) input prions; (B) cofactor PrPSc; (C) PE PrPSc; (D) serial-passage PE PrPSc. OSU, red
squares; Me7, blue circles; 301C, green triangles. Mean values ± SEM of three replicates are shown for each point.
E1944 | www.pnas.org/cgi/doi/10.1073/pnas.1206999109 Deleault et al.
then was transformed into Escherichia coli Rosetta Cells (EMD Chemicals).
Cells were grown overnight in 1 L of LB medium (5 g yeast extract, 10 g
Bacto tryptone, 10 g NaCl) supplemented with the Overnight Express
Autoinduction System (EMD Chemicals). The next day the cells were centri-
fuged at 8,000 × g for 10 min, and the supernatant was discarded. Pellets
were resuspended in a solution of 1× Bug Buster and 10 μL Lysonase (EMD
Chemicals) containing EDTA-free Complete protease inhibitors (Roche). Cells
then were incubated on ice and lysed using intermittent sonication for
20 min. The lysate was centrifuged at 16,000 × g for 20 min and was washed
twice with 0.1× Bug Buster. The resulting inclusion bodies were solubilized
using 8 M guanidine HCl and physical agitation, and insoluble material was
removed by centrifugation at 8,000 × g for 15 min. PrP then was purified as
described previously (22).
Cofactor Preparation. The protocol for isolating the cofactor preparation and
details about its composition have been described previously (21). All cen-
trifugation was done at 4 °C unless otherwise noted. A 10% (wt/vol) brain
homogenate was made by processing 0.5 g normal mouse brain in 4.5 mL of
20 mM 3-(N-morpholino)propanesulfonic acid (Mops) (pH 7.0), 150 mM NaCl
with a Potter homogenizer. Debris was removed by centrifugation at 200 × g
for 30 s. The postnuclear supernatant was centrifuged for 30 min at 10,000 × g,
and the resulting pellet was rehomogenized in 4.5 mL of 20 mM Mops
(pH 7.0), 150 mM NaCl containing 3% (wt/vol) N-octyl-β-D-glucopyranoside
(NOG) (Anatrace) and incubated at room temperature for 30 min. Next, the
homogenate was centrifuged at 100,000 × g for 60 min. The resulting su-
pernatant was adjusted to 2 mM CaCl2 and 150 U/mL S7 nuclease (Roche)
and was incubated at 37 °C for 30 min using an end-over-end rotator.
Thermolysin (Sigma) was added at a final concentration of 25 μg /mL, and the
sample was incubated at 70 °C for 60 min with intermittent mixing. Next, the
sample was cooled on ice, adjusted to 5 mM EDTA, and centrifuged for 1 h at
100,000 × g. The supernatant then was placed in cellulose ester dialysis tubing
with a 20,000 Molecular Weight Cutoff (Spectrum Laboratories) and dialyzed
at 4 °C against water. Following dialysis, the sample centrifuged for 3 h
at 100,000 × g. The supernatant was discarded, and the pellet was resus-
pended in 1 mL of deionized water by trituration (one-fifth of the original
homogenate volume).
sPMCA. For experiments comparing cofactor PrPSc with protein-only PrPSc
molecules, reconstituted sPMCA reactions were conducted as previously
reported (20), with the following modifications. Sonication pulses were 15 s
every 30 min with power output ∼215 W, and 100 μL reactions contained
6 μg /mL recombinant mouse PrP (MoPrP), 20 mM Tris (pH 7.5), 135 mM NaCl,
5 mM EDTA (pH 7.5), 0.15% (vol/vol) Triton X-100 supplemented with either
cofactor or water as indicated. The original recPrPSc seed used for these
experiments was generated de novo by F.W. as previously described (22) and
then was propagated by sPMCA with recPrP and purified cofactor by N.R.D.
Cofactor PrPSc and protein-only PrPSc samples were propagated by sPMCA
(18 rounds) using the same recPrPSc seed and base substrate mixture (with
the addition of either cofactor for cofactor PrPSc samples or water for pro-
tein-only PrPSc samples, as indicated) and were processed in parallel in
concentric positions relative to the center of the same microplate horn.
For experiments comparing different prion strains as seed, 100-μL reac-
tions contained 6 μg /mL recombinant MoPrP, 20 mM Tris (pH 7.5), 135 mM
NaCl, 5 mM EDTA (pH 7.5), 0.15% (vol/vol) Triton X-100, and either 25 μL
purified cofactor or 10 mM plasmalogen PE [resuspended in 0.05% (vol/vol)
Triton X-100]. Day 1 reactions were seeded with 10 μL of scrapie brain ho-
mogenate diluted 1:10 in PBS or with 10 μL recPrPSc. Samples were sonicated
with 15-s pulses every 30 min for 24 h at 37 °C. After each 24-h period, 1/10th
of the reaction volume was transferred to a different tube containing fresh
substrate mixture, and the 24-h cycle of sonication was repeated. To prevent
cross-contamination between samples, all tubes were sealed with Parafilm
(Pechiney Plastic Packaging Company) and clamped shut using a plastic
holder (30). Separate strains were propagated at different times in separate
sonicator horns (either new or presoaked in 100% bleach) to avoid the
possibility of cross-contamination between strains. Each sample was propa-
gated for 18 rounds to eliminate the original seed by serial dilution. The
effectiveness of this dilution was confirmed for each sample by performing
mock propagation reactions of seeded samples lacking PrP substrate for 18
rounds. The lack of infectivity in these mock-propagated samples confirmed
the adequacy of serial dilution to eliminate the original seed as well as our
ability to prevent cross-contamination. To confirm that our substrate
materials and inocula were not contaminated, we inoculated unseeded
substrate mixture that was not subjected to sPMCA.
Seeded sPMCA experiments using normal mouse brain homogenate as
substrate were performed as previously described (33).
PrPSc Detection. To detect PrPSc molecules in either the products of PMCA
reactions or brain homogenates (5% wt/vol in PBS 0.5% (vol/vol) Triton X-
100), samples were digested with 25 μg/mL proteinase K for 30 min at 37 °C.
All samples were processed for SDS/PAGE and Western blotting as previously
described (29), substituting Towbin transfer buffer (34) and using mAb 6D11
as the primary antibody. SDS/PAGE signals were quantified using Image
Gauge v4.22 (Fujifilm). PrP levels were determined semiquantitatively by
comparison with a dilution series of recPrP as standard.
Scrapie Inoculation and Diagnosis. Samples containing PMCA products were
prepared and serially diluted in sterile PBS 1% (wt/vol) BSA. PMCA samples
were diluted directly 1:10 (i.e., without prior concentration) to generate the
10−1 titer sample. Samples of brain homogenates were adjusted to 1% (wt/
vol) final concentration in PBS 1% (wt/vol) BSA for inoculation. Intracerebral
inoculations (using a volume of 30 μL) and scrapie diagnosis in C57BL female
mice were performed as described previously (20).
Neuropathology. Mice were killed, and brains were removed rapidly using
new, sterile-packaged dissection instruments and disposable surfaces to avoid
cross-contamination. Brains were immersion-fixed in 10% (wt/vol) buffered
formalin for 2–30 d, cut into ∼3-mm-thick sagittal sections, and placed in
a tissue-processing cassette. Cassettes were treated with 88% formic acid for
1 h and then were stored in PBS. The tissue was processed for paraffin
embedding, and representative slides were stained with H&E. Immunohis-
tochemistry was performed on deparaffinized slides using 2 μg/mL 27/33
anti-PrP mAb for 30 min at room temperature after citrate antigen retrieval
and a Biocare Mouse on Mouse development kit. Blinded scoring for vacu-
olation and PrP deposition was performed using standard scales as described
previously (20).
Atomic Force Microscopy. PMCA reactions were pooled to a total volume of
1,250 μL. Each tube received 100 μL of a 50% (vol/vol) slurry of immobilized
L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin
(catalog no. 20230; Thermo Scientific) and was incubated overnight at 37 °C
while rotating end over end. The next morning each tube was centrifuged
briefly to pellet the agarose beads. After the supernatant was removed,
each tube was centrifuged at 100,000 × g for 1 h. A 250-μL pellet was
resuspended to 1,200 μL in 3% (wt/vol) NOG and then was centrifuged at
100,000 × g for 1 h. Again, a 250-μL pellet was washed with 3% (wt/vol) NOG
followed by two washes in 1 mL of water. The final pellet was vortexed for
20 s, sonicated for 20 s at power 65, and vortexed again for 20 s. A small
amount then was treated with 25 μg/mL of proteinase K, and the concen-
tration was determined by Western blot and densitometry.
Samples were scanned by atomic force microscopy as previously described
(33). Briefly, images were captured in tapping mode using two different tips
[TAP300AL cantilever with a tip radius <10 nm and a force constant of 40 N/m
(Budget Sensors) or SSS-NCHR cantilever with a tip radius <2 nm and a force
constant of 42 N/m (Nanosensors)]. Each sample (15 μL) was laid down on
a piece of freshly cleaved mica and allowed to dry under nitrogen. Samples
were rinsed three timeswith 150 μL ofwater. Datawere collected as 512× 512
pixel images, using multiple samples and several scanning sessions. Images
were exported using Gwyddion 2.19 software (Czech Metrology Institute).
Fluorescence Double-Color Assay. Two hundred microliters of recPrPSc [pre-
pared by three rounds sPMCA using 0.5 mM NBD-PE (Avanti Polar Lipids) as
a cofactor] was adjusted to 1.5-mL total volume with PBS 1% (vol/vol) Triton,
centrifuged at 100,000 × g for 1 h, and washed three times with PBS 3% (wt/
vol) NOG and once with PBS. The pellet was resuspended in 100 μL 10 mM
acetate buffer, pH 5.0, and incubated for 1 h at room temperature and then
overnight at 4 °C in a Permanox eight-well Lab-Teks chamber slide system
(Nunc) in 10 mM sodium acetate, pH 5.0. The following day, the samples were
fixed to the slide by the addition of 150 μL of PBS, 8% (vol/vol) formaldehyde
and incubation at room temperature for 15 min. Unfixed sample was
removed by aspiration, and each slide well was washed once with 150 μL of
PBS. Then 150 μL of mAb D13 diluted 1:250 in PBS + 4% (wt/vol) BSA was
applied to each slide well and allowed to incubate overnight at 4 °C or for 2 h
at room temperature in a humidified chamber. After primary antibody
incubation, the slide well was washed three times with 150 μL of PBS + 4%
(wt/vol) BSA and was allowed to incubate for 15 min at room temperature
during each wash. Then150 μL of secondary antibody, sheep anti-mouse con-
jugated with Alexa Fluor 568 (Invitrogen), diluted 1:250 in PBS + 4% (wt/vol)
BSA, was applied to each slide and allowed to incubate for 2 h in the dark at
room temperature in a humidified chamber. The slide well then was washed
three times with 150 μL of PBS + 4% (wt/vol) BSA and was allowed to in-
cubate for 15 min at room temperature during each wash. ProLong Antifade
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solution (15 μL) (Invitrogen) was added to each sample and 18-mm2 glass
coverslips (catalog no. 1.5; Corning) were mounted on each slide and allowed
to dry overnight in the dark in a desiccating chamber. We also prepared and
analyzed a control slide coated with reaction buffer only and then stained
with D13 mAb and Alexa Fluor 568 secondary antibody to rule out non-
specific binding of either antibody to the slide. A slide coated only with NBD-
PE in reaction buffer was prepared to rule out nonspecific binding of NBD-PE
to the slide. Finally, a slide coated with PrPSc in reaction buffer that did not
contain NBD-PE was prepared to rule out autofluorescence of PrPSc in the
NBD excitation wavelength. Samples were analyzed visually using a Zeiss
Axioplan 2 wide-field fluorescence microscope, and digital images were cap-
tured with Phylum Live 4.2.1 software (Improvision).
Statistical Methods. We used nonparametric approaches to compare the
vacuolation characteristics in seven brain regions and immunohistochemical
(IHC) deposition in eight brain regions of animals inoculated with OSU input
(n = 5), Me7 input (n = 6), 301C input (n = 5), OSU cofactor (n = 6), Me7
cofactor (n = 8), 301 cofactor (n = 8), OSU PE (n = 7), Me7 PE (n = 5), or 301C
PE (n = 7). Specifically, we used Mann–Whitney tests to compare IHC char-
acteristics in each brain region from each input strain (OSU, Me7, and 301C)
with its corresponding cofactor strain. We used Kruskal–Wallis equality-of-
populations rank tests to assess the probability that the IHC characteristics
seen within each brain region for the six output strains represented a single
distribution. We repeated the analysis including all nine strains to test the
hypothesis that the IHC patterns for all nine strains represent a single dis-
tribution. We defined P < 0.05 as statistically significant. Data were analyzed
using Stata 12.0 (Stata Corporation).
Enzymatic Deglycosylation. Various 10% brain homogenates were normalized
for PrP scrapie content by dilution in PrnP0/0 brain homogenate. Seventy-five
microliters of each homogenate was added to 25 μL of PBS, 2% (vol/vol)
Triton X-100 containing 40 μg/mL proteinase K, and samples were shaken at
750 rpm for 30 min at 37 °C. After incubation, 5 μL of 200 mM PMSF (in 100%
EtOH) was added, and the sample was vortexed and incubated at room
temperature for 10 min. Next, samples were diluted with 895 μL PBS, 0.5%
(vol/vol) Triton X-100 and were centrifuged at 100,000 × g for 60 min at 4 °C,
and supernatants were discarded. Pellets then were resuspended in 20 μL of
5× glycoprotein denaturation buffer, subjected to three 30-s bursts of son-
ication, and boiled at 95 °C for 10 min. Samples then were diluted with 80 μL
water, and sonication and boiling were repeated. Next, samples were cooled
to room temperature, and 13 μL each of 10× G7 reaction buffer and 10% (vol/
vol) Nonidet P-40 and 5 μL of peptide:N-glycosidase F (PNGase F) were added
to each sample. Samples were incubated overnight at 37 °C. Reactions were
stopped by the addition of 44 μL of 4× SDS sample buffer and boiling at 95 °C
for 10 min.
Urea Denaturation Assay. Thirty microliters of 10% (wt/vol) brain homogenate
was mixed with 120 μL of various urea/0.25% (vol/vol) Triton X-100 solutions
to obtain final urea concentrations between 0 and 8 M. Samples then were
incubated at 60 °C for 3 h with shaking at 750 rpm. Next, 100 μL of 50 mM
Mops (pH 7.0) containing 330 mM NaCl, 1% (vol/vol) Triton X-100, and 125
μg/mL proteinase K was added, and samples were incubated at 37 °C for 45–
60 min, with shaking at 750 rpm. Then 84 μL of 4× SDS sample buffer was
added, and samples were boiled for 10 min at 95 °C. SDS/PAGE signals were
quantified using Image Gauge v4.22 (Fujifilm).
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